Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer.

Gen KawaguchiKohei AkazawaTaro IkedaYohei IkedaNoboru HaraTsutomu Nishiyama

Published in: SAGE open medicine (2023)

Prostate-specific antigen doubling time after the Ra-223 treatment is a useful predictor of the clinical course following treatment in metastatic castration-resistant prostate cancer patients.

Keyphrases

rheumatoid arthritis
end stage renal disease
small cell lung cancer
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
combination therapy
replacement therapy